keyword
MENU ▼
Read by QxMD icon Read
search

"RSV vaccine"

keyword
https://www.readbyqxmd.com/read/29780032/severe-outcomes-associated-with-respiratory-viruses-in-newborns-and-infants-a-prospective-viral-surveillance-study-in-jordan
#1
Najwa Khuri-Bulos, Lindsey Lawrence, Bhinnata Piya, Li Wang, Christopher Fonnesbeck, Samir Faouri, Asem Shehabi, Sten H Vermund, John V Williams, Natasha B Halasa
OBJECTIVE: To assess virus-specific hospitalisation rates, risk factors for illness severity and seasonal trends in children hospitalised with acute respiratory infections (ARI). DESIGN: Prospective cohort study. SETTING: A government hospital serving low-income and middle-income population in Amman, Jordan. PARTICIPANTS: Children under 2 years of age hospitalised with fever and/or respiratory symptoms (n=3168) from 16 March 2010 to 31 March 2013...
May 20, 2018: BMJ Open
https://www.readbyqxmd.com/read/29779923/a-viral-vectored-rsv-vaccine-induces-long-lived-humoral-immunity-in-cotton-rats
#2
Jessica L Grieves, Zhiwei Yin, Adolfo Garcia-Sastre, Ignacio Mena, Mark E Peeples, Heidi P Risman, Hannah Federman, Marvin J Sandoval, Russell K Durbin, Joan E Durbin
Human respiratory syncytial virus (RSV) is the leading cause of lower airway disease in infants worldwide and repeatedly infects immunocompetent individuals throughout life. Severe lower airway RSV infection during infancy can be life-threatening, but is also associated with important sequelae including development of asthma and recurrent wheezing in later childhood. The basis for the inadequate, short-lived adaptive immune response to RSV infection is poorly understood, but it is widely recognized that RSV actively antagonizes Type I interferon (IFN) production...
May 17, 2018: Vaccine
https://www.readbyqxmd.com/read/29771625/a-multifaceted-approach-to-rsv-vaccination
#3
Jorge C G Blanco, Marina S Boukhvalova, Trudy G Morrison, Stefanie N Vogel
Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, resulting in significant morbidity and mortality worldwide. In addition, RSV infections occur throughout different ages, thus, maintaining the virus in circulation, and increasing health risk to more susceptible populations such as infants, the elderly, and the immunocompromised. To date, there is no vaccine approved to prevent RSV infection or minimize symptoms of infection. Current clinical trials for vaccines against RSV are being carried out in four very different populations...
May 17, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29686673/the-cd8-t-cell-response-to-respiratory-virus-infections
#4
REVIEW
Megan E Schmidt, Steven M Varga
Humans are highly susceptible to infection with respiratory viruses including respiratory syncytial virus (RSV), influenza virus, human metapneumovirus, rhinovirus, coronavirus, and parainfluenza virus. While some viruses simply cause symptoms of the common cold, many respiratory viruses induce severe bronchiolitis, pneumonia, and even death following infection. Despite the immense clinical burden, the majority of the most common pulmonary viruses lack long-lasting efficacious vaccines. Nearly all current vaccination strategies are designed to elicit broadly neutralizing antibodies, which prevent severe disease following a subsequent infection...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29678551/anti-respiratory-syncytial-virus-rsv-g-monoclonal-antibodies-reduce-lung-inflammation-and-viral-lung-titers-when-delivered-therapeutically-in-a-balb-c-mouse-model
#5
Hayat Caidi, Congrong Miao, Natalie J Thornburg, Ralph A Tripp, Larry J Anderson, Lia M Haynes
RSV continues to be a high priority for vaccine and antiviral drug development. Unfortunately, no safe and effective RSV vaccine is available and treatment options are limited. Over the past decade, several studies have focused on the role of RSV G protein on viral entry, viral neutralization, and RSV-mediated pathology. Anti-G murine monoclonal antibody (mAb) 131-2G treatment has been previously shown to reduce weight loss, bronchoalveolar lavage (BAL) cell number, airway reactivity, and Th2-type cytokine production in RSV-infected mice more rapidly than a commercial humanized monoclonal antibody (mAb) against RSV F protein (Palivizumab)...
April 17, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29678177/healthcare-resource-use-and-economic-burden-attributable-to-respiratory-syncytial-virus-in-the-united-states-a-claims-database-analysis
#6
Caroline Amand, Sabine Tong, Alexia Kieffer, Moe H Kyaw
BACKGROUND: Despite several studies that have estimated the economic impact of Respiratory Syncytial Virus (RSV) in infants, limited data are available on healthcare resource use and costs attributable to RSV across age groups. The aim of this study was to quantify age-specific RSV-related healthcare resource use and costs on the US healthcare system. METHODS: This retrospective case-control study identified patients aged ≥1 year with an RSV event in the Truven Health Marketscan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases between August 31, 2012 and August 1, 2013...
April 20, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29622165/respiratory-syncytial-virus-and-associations-with-cardiovascular-disease-in-adults
#7
REVIEW
Kelsey S Ivey, Kathryn M Edwards, H Keipp Talbot
Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV...
April 10, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29617879/prevalence-and-significance-of-substitutions-in-the-fusion-protein-of-respiratory-syncytial-virus-resulting-in-neutralization-escape-from-antibody-medi8897
#8
Qing Zhu, Bin Lu, Patrick McTamney, Susan Palaszynski, Seme Diallo, Kuishu Ren, Nancy D Ulbrandt, Nicole Kallewaard, Weijia Wang, Fiona Fernandes, Steve Wong, Catherine Svabek, Brian Moldt, Mark T Esser, Hong Jing, JoAnn A Suzich
Background: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among infants and young children. To date, no vaccine is approved for the broad population of healthy infants. MEDI8897, a potent anti-RSV fusion antibody with extended serum half-life is currently under clinical investigation as a potential passive RSV vaccine for all infants. As an RNA virus, RSV is prone to mutation, the possibility of viral escape from MEDI8897 neutralization is a potential concern...
March 30, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29599087/a-novel-method-for-strict-intranasal-delivery-of-non-replicating-rsv-vaccines-in-cotton-rats-and-non-human-primates
#9
Michael P Citron, Manishkumar Patel, Mona Purcell, Shu-An Lin, Daniel J Rubins, Paul McQuade, Cheryl Callahan, Alexa Gleason, Ioan Petrescu, Walter Knapp, Chinedu Orekie, Sai Chamarthy, Zhiyun Wen, Sinoeun Touch, Matthew Pine, Jane Fontenot, Cameron Douglas, Xiaoping Liang, Amy S Espeseth
Respiratory syncytial virus (RSV) is the most common viral cause of bronchiolitis and pneumonia in children twelve months of age or younger and a significant cause of lower respiratory disease in older adults. As various clinical and preclinical candidates advance, cotton rats (Sigmodon hispidus) and non-human primates (NHP) continue to play a valuable role in RSV vaccine development, since both animals are semi-permissive to human RSV (HRSV). However, appropriate utilization of the models is critical to avoid mis-interpretation of the preclinical findings...
March 26, 2018: Vaccine
https://www.readbyqxmd.com/read/29560833/meteorological-factors-and-respiratory-syncytial-virus-seasonality-in-subtropical-australia
#10
C Morley, K Grimwood, S Maloney, R S Ware
Evidence is emerging regarding the influence of meteorological factors on seasonal respiratory syncytial virus outbreaks. Data however, are limited for subtropical regions, especially in the southern hemisphere. We examined whether meteorological data (daily minimum and maximum temperatures, rainfall, relative humidity, dew point, daily global solar exposure) and tourist numbers were associated with the incidence of RSV in children aged <5 years for the Gold Coast region of South-East Queensland, Australia (latitude 28...
April 2018: Epidemiology and Infection
https://www.readbyqxmd.com/read/29559168/the-respiratory-syncytial-virus-fusion-protein-formulated-with-a-polymer-based-adjuvant-induces-multiple-signaling-pathways-in-macrophages
#11
Indranil Sarkar, Ravendra Garg, Sylvia van Drunen Littel-van den Hurk
Respiratory syncytial virus (RSV) causes acute respiratory tract infections in infants, the elderly and immunocompromised individuals. No licensed vaccine is available against RSV. We previously reported that intranasal immunization of rodents and lambs with a RSV vaccine candidate (ΔF/TriAdj) induces protective immunity with a good safety profile. ΔF/TriAdj promoted innate immune responses in respiratory mucosal tissues in vivo, by local chemokine and cytokine production, as well as infiltration and activation of immune cells including macrophages...
April 19, 2018: Vaccine
https://www.readbyqxmd.com/read/29552008/induction-and-subversion-of-human-protective-immunity-contrasting-influenza-and-respiratory-syncytial-virus
#12
REVIEW
Stephanie Ascough, Suzanna Paterson, Christopher Chiu
Respiratory syncytial virus (RSV) and influenza are among the most important causes of severe respiratory disease worldwide. Despite the clinical need, barriers to developing reliably effective vaccines against these viruses have remained firmly in place for decades. Overcoming these hurdles requires better understanding of human immunity and the strategies by which these pathogens evade it. Although superficially similar, the virology and host response to RSV and influenza are strikingly distinct. Influenza induces robust strain-specific immunity following natural infection, although protection by current vaccines is short-lived...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29546402/virus-specific-antibody-viral-load-and-disease-severity-in-respiratory-syncytial-virus-infection
#13
Edward E Walsh, Lu Wang, Ann R Falsey, Xing Qiu, Anthony Corbett, Jeanne Holden-Wiltse, Thomas J Mariani, David J Topham, Mary T Caserta
Background: Maternally derived serum antibody and viral load are thought to influence disease severity in primary Respiratory Syncytial Virus (RSV) infection. As part of the AsPIRES study of RSV pathogenesis we correlated various serum antibody concentrations and viral load with disease severity. Methods: Serum neutralizing titers and IgG to RSV F, Ga and Gb proteins, the CX3C region of G, and nasal viral load were measured in 139 full-term previously healthy infants with primary RSV infection and correlated with illness severity...
March 13, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29509929/live-respiratory-syncytial-virus-rsv-vaccine-candidate-containing-stabilized-temperature-sensitivity-mutations-is-highly-attenuated-in-rsv-seronegative-infants-and-children
#14
Ursula J Buchholz, Coleen K Cunningham, Petronella Muresan, Devasena Gnanashanmugam, Paul Sato, George K Siberry, Vivian Rexroad, Megan Valentine, Charlotte Perlowski, Elizabeth Schappell, Bhagvinji Thumar, Cindy Luongo, Emily Barr, Mariam Aziz, Ram Yogev, Stephen A Spector, Peter L Collins, Elizabeth J McFarland, Ruth A Karron
Background: Respiratory syncytial virus (RSV) is the most important viral cause of severe respiratory illness in young children and lacks a vaccine. RSV cold-passage/stabilized 2 (RSVcps2) is a modification of a previously evaluated vaccine candidate in which 2 major attenuating mutations have been stabilized against deattenuation. Methods: RSV-seronegative 6-24-month-old children received an intranasal dose of 105.3 plaque-forming units (PFU) of RSVcps2 (n = 34) or placebo (n = 16) (International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1114 and companion protocol CIR285)...
April 11, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29470837/past-present-and-future-approaches-to-the-prevention-and-treatment-of-respiratory-syncytial-virus-infection-in-children
#15
REVIEW
Eric A F Simões, Louis Bont, Paolo Manzoni, Brigitte Fauroux, Bosco Paes, Josep Figueras-Aloy, Paul A Checchia, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence - A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, present and future approaches to the prevention and treatment of RSV infection among infants and children. METHODS: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2017 across PubMed, Embase and The Cochrane Library...
March 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29466748/infants-harness-the-germline-against-rsv
#16
Annette Fox, Kanta Subbarao, Patrick Reading
In this issue of Immunity, Goodwin et al. (2018) offer hope for an RSV vaccine for young infants by demonstrating that RSV infection in very young infants induces neutralizing antibodies that are close to the germline and have unusual epitope specificity.
February 20, 2018: Immunity
https://www.readbyqxmd.com/read/29460719/characterization-of-cotton-rat-sigmodon-hispidus-eosinophils-including-their-response-to-respiratory-syncytial-virus-infection
#17
M Gia Green, Natasha Petroff, Krista M D La Perle, Stefan Niewiesk
Eosinophils have been postulated to play a protective role against infection with respiratory syncytial virus (RSV), increase the severity of allergic asthma during respiratory viral infection, and drive vaccine-enhanced disease. To address these questions in the cotton rat model of RSV infection, we characterized cotton rat eosinophils by electron microscopy as well as by bronchoalveolar lavage and histology of lung sections. Using these methods, we demonstrated that eosinophils comprise approximately half of all cells in the bronchoalveolar lavage fluids from cotton rats...
February 1, 2018: Comparative Medicine
https://www.readbyqxmd.com/read/29439869/immunization-with-an-adjuvanted-low-energy-electron-irradiation-inactivated-respiratory-syncytial-virus-vaccine-shows-immunoprotective-activity-in-mice
#18
Lea Bayer, Jasmin Fertey, Sebastian Ulbert, Thomas Grunwald
Respiratory syncytial virus (RSV) is a pathogen causing severe lower respiratory tract disease in infants and the elderly. In spite of the great need for a vaccine against RSV, currently there is no licensed product on the market. A very early vaccine candidate developed in the 1960s based on formaldehyde inactivation (FI) turned out to instead enhance the disease. Our novel inactivation method applied low-energy electron irradiation (LEEI) to produce a killed RSV vaccine. LEEI yielded inactivated virus particles with a reproducible virus antigen conservation above 70%, while FI resulted in highly variable antigen conservation...
March 14, 2018: Vaccine
https://www.readbyqxmd.com/read/29401325/safety-and-immunogenicity-of-3-formulations-of-an-investigational-respiratory-syncytial-virus-vaccine-in-nonpregnant-women-results-from-2-phase-2-trials
#19
Jiri Beran, Jason D Lickliter, Tino F Schwarz, Casey Johnson, Laurence Chu, Joseph B Domachowske, Pierre Van Damme, Kanchanamala Withanage, Laurence A Fissette, Marie-Pierre David, Koen Maleux, Alexander C Schmidt, Marta Picciolato, Ilse Dieussaert
Background: Respiratory syncytial virus (RSV) causes bronchiolitis and pneumonia in neonates and infants. RSV vaccination during pregnancy could boost preexisting neutralizing antibody titers, providing passive protection to newborns. Methods: Two observer-blinded, controlled studies (RSV F-020 [clinical trials registration NCT02360475] and RSV F-024 [NCT02753413]) evaluated immunogenicity and safety of an investigational RSV vaccine in healthy, nonpregnant 18-45-year-old women...
April 23, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29396163/infants-infected-with-respiratory-syncytial-virus-generate-potent-neutralizing-antibodies-that-lack-somatic-hypermutation
#20
Eileen Goodwin, Morgan S A Gilman, Daniel Wrapp, Man Chen, Joan O Ngwuta, Syed M Moin, Patricia Bai, Arvind Sivasubramanian, Ruth I Connor, Peter F Wright, Barney S Graham, Jason S McLellan, Laura M Walker
Respiratory syncytial virus (RSV) is a leading cause of infant mortality, and there are currently no licensed vaccines to protect this vulnerable population. A comprehensive understanding of infant antibody responses to natural RSV infection would facilitate vaccine development. Here, we isolated more than 450 RSV fusion glycoprotein (F)-specific antibodies from 7 RSV-infected infants and found that half of the antibodies recognized only two antigenic sites. Antibodies targeting both sites showed convergent sequence features, and structural studies revealed the molecular basis for their recognition of RSV F...
February 20, 2018: Immunity
keyword
keyword
66261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"